Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — AusBiotech Invest 2025
18 slides from Arovella Therapeutics's conference presentation, Oct 21, 2025
Slide 1: AusBiotech Invest Presentation (ASX Release)
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 21 October 2025 AUSBIOTECH INVEST PRESENTATION Highlights: • Arovella presents at AusBiotech Invest 2025 For personal use only MELBOURNE, AUSTRALIA 21 October 2025: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focuse
Slide 2: Notes to Editors: About Arovella Therapeutics
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 NOTES TO EDITORS: About Arovella Therapeutics Ltd Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cance
Slide 3: AusBiotech Invest 2025
ASX:ALA For personal use only AusBiotech Invest 2025 ASX: ALA
Slide 4: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment advice. 4. Whilst this presentation is based on information from sources which are considered The presentation is not intended to be comprehensive or provide all information reliable, no representation or warr
Slide 5: Arovella's Investment Highlights
Arovella’s Investment Highlights Off-the-Shelf iNKT Strong Cell Platform Leadership Group For personal use only Developing off-the-shelf iNKT Leadership team and Board cell therapies to target blood have proven experience in drug cancers and solid tumour development, particularly cell cancers therap
Slide 6: Financial overview
Financial overview Financial Snapshot ASX CODE ALA ALA Price and Volume - 12 Months1 For personal use only Market capitalisation1 $113.72 million 40,000,000 Shares on issue 1,197.0 million $0.18 52-week low / high $0.068 / $0.210 Cash Balance (30 Jun, 2025) $20.9 million 30,000,000 $0.12 Major Share
Slide 7: Recent cell therapy transactions
Recent cell therapy transactions1 Upfront Milestones Total deal Date Type of deal Acquirer/Licensee Target/Licensor Cell Type Stage (US$M) (US$M) value (US$M) Oct-25 Acquisition In vivo CAR Preclinical $1,500 $0 $1,500 Aug-25 Acquisition In vivo CAR Phase 1 $350 $0 $350 For personal use only Jun-25
Slide 8: How original CAR-T cell therapies work
How original CAR-T cell therapies work CAR-T cell therapy is personalised medicine T cells = immune cell For personal use only T cells are a common type of immune cell that fight infections and can help fight cancer. T cells from patient ‘reprogrammed’ To generate autologous CAR-T cells, T cells are
Slide 9: Emily Whitehead - Celebrating Years of CAR T-Cell Therapy
For personal use only Emily Whitehead - Celebrating 10 Years of CAR T-Cell Therapy https://emilywhiteheadfoundation.org/10-years-of-car-t/ ASX:ALA 7
Slide 10: Current CAR-T technology challenges and ALA's solution
Current CAR-T technology challenges ALA’s solution: One CAR-T product only treats the patient who supplied the T cells One CAR-iNKT batch from Manufacturing & supply a healthy donor treats multiple For personal use only T cell chain costs are high patients T cell Each manufacturing T cells can be co
Slide 11: Introducing invariant Natural Killer T (iNKT) cells
Introducing invariant Natural Killer T (iNKT) cells Bridging the innate and adaptive immune system For personal use only Innate Immunity Adaptive Immunity ASX:ALA 9
Slide 12: iNKT cells represent a next-generation cell therapy
iNKT cells represent a next-generation cell therapy Properties make them ideal for use in cell therapy Strong safety profile For personal use only Invariant receptor recognizes the same molecule (CD1d) in all people Innate Don’t cause graft versus host disease (GvHD)1 Immunity Front line of the
Slide 13: A differentiated position
A differentiated position T cell and NK cell sectors are competitive For personal use only T cell iNKT cell NK cell Companies with T cell, NK cell, or iNKT cell therapy programs. ASX:ALA Source: Company analysis based on public information 11
Slide 14: Arovella's path to patient
Arovella’s path to patient TECHNOLOGY PRE-CLINICAL LENTIVIRUS MANUFACTURING PHASE 1 CLINICAL PHASE 2 CLINICAL PRODUCT FDA (IND) ACQUISITION CONFIRMATION MANUFACTURING PLATFORM TRIAL TRIAL For personal use only CD19-iNKT Early Lymphoma ALA-101 2026 CLDN18.2-iNKT Gastric Cancer ALA-105 CAR-iNKT Other
Slide 15: Arovella's expanding pipeline
Arovella’s expanding pipeline For personal use only ASX:ALA 13
Slide 16: Upcoming milestones for FY2026
Upcoming milestones for FY2026 Jul Dec Jun 2025 2025 2026 For personal use only • Complete cGMP manufacture and IND enabling studies • Commence phase 1 study and generate initial data and file an IND application with US FDA for phase 1 from patients in early dose cohorts ALA-101 • Complete preparato
Slide 17: Thank You
ASX:ALA For personal use only Thank You Dr. Michael Baker CEO & Managing Director Email: investor@arovella.com Mobile: +61 403 468 187
Slide 18: Cell therapy deal references
Cell therapy deal references 1. https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Strengthens-and-Diversifies-Cell-Therapy-Portfolio-with-Acquisition-of-Orbital- Therapeutics/default.aspx 2. https://interiusbio.com/press-release/kite-to-acquire-interius-biotherapeutics-to-advan